Overall, 12 deaths were reported, including 4 related to autoHSCT. The 100-day non-relapse-mortality (NRM) and 1-year NRM were 14% and 24%, respectively. The authors concluded that autoHSCT is a feasible option for relapsed PTLD; however, due to the high associated infectious-driven NRM,...